<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125911">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709474</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ALE05</org_study_id>
    <nct_id>NCT01709474</nct_id>
  </id_info>
  <brief_title>Vitamin D3 in Pediatric SLE</brief_title>
  <official_title>Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Autoimmunity Centers of Excellence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the impact of 18 weeks of high-dose
      vitamin D3 supplementation vs. standard-dose vitamin D3 supplementation on immune
      hyperactivation as measured by the interferon (IFN) signature in a pediatric population
      diagnosed with systemic lupus erythematosus (SLE) and vitamin D deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, phase II, 18-week, two arm, unblinded, mechanistic randomized
      clinical trial to evaluate the effects of high-dose vitamin D3 supplementation compared with
      standard-dose supplementation, on immune function, glucose homeostasis, and bone metabolism.

      Seventy-eight pediatric subjects with SLE and 25(OH)D levels ≤ 20 ng/mL will be randomized
      in a 1:1 ratio to receive either standard-dose (400 IU/day) or highdose (6,000 IU/day)
      vitamin D3 for 18 weeks based upon weight at baseline. Subjects randomized to the high-dose
      vitamin D3 treatment arm will receive 6,000 IU per day from baseline until the subject's
      vitamin D levels reach ≥ 40 ng/mL at which point the vitamin D3 dose will be reduced to
      4,000 IU per day. Subjects randomized to the high-dose treatment arm weighing &lt; 40 kg will
      receive supplementation five days per week and all other subjects will receive
      supplementation seven days a week.

      In addition to the baseline, and weeks 6, 12, and 18 visits, subjects randomized to the
      high-dose treatment arm will return at Weeks 3 and 9 to assess vitamin D toxicity. If a
      subject in the high-dose arm is found to exhibit evidence of vitamin D toxicity at the week
      12 visit, he/she will be asked to return to the site for an additional vitamin D toxicity
      assessment at week 15. Study personnel will record each subject's interval history, assess
      adverse events, disease activity, and collect samples for safety and mechanistic
      assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change in average IFN module expression level</measure>
    <time_frame>baseline to week 18</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects in each study arm experiencing any adverse event (AE) ≥ Grade 3</measure>
    <time_frame>baseline to 18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event grading based on National Cancer Institute— Common Terminology Criteria for Adverse Events (NCI-CTCAE)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>High Dose Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the high-dose arm will receive 6,000 IU per day until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 IU/day of vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>High Dose Vitamin D3</arm_group_label>
    <arm_group_label>Low Dose Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent signed by the subject or parent/guardian as appropriate;
             child assent as appropriate

          -  Before the age of 19, met at least 4 of the 11 modified American College of
             Rheumatology (ACR) 1982 Revised Criteria for the Classification of Systemic Lupus
             Erythematosus as updated in 1997.

          -  Date of SLE diagnosis (as described in Inclusion Criterion 2) at least 24 weeks prior
             to randomization

          -  Serum 25(OH) D &lt; 20 ng/mL at Screening

          -  SELENA SLEDAI score &gt; 0 and &lt; 8 at Screening and at Baseline

          -  If taking prednisone (or equivalent corticosteroid), the dose must be ≤ 15 mg/day or
             ≤ 0.5 mg/kg/day, whichever is lower, and stable for at least four weeks prior to
             randomization. Note, if subjects are taking steroids every other day, divide their
             dose by 2 to evaluate eligibility.

          -  Stable immunosuppressive dose for at least 12 weeks prior to randomization.
             Immunosuppressive medications allowed include mycophenolate, azathioprine,
             methotrexate, antimalarial medications (e.g., hydroxychloroquine), cyclosporine A,
             tacrolimus, IVIG, and abatacept

          -  Body weight &gt; 25 kg

          -  Able to swallow pills at randomization

          -  Males and females with reproductive potential must agree to practice effective
             measures of birth control

        Exclusion Criteria:

          -  Any condition or treatment that, in the opinion of the investigator, places the
             subject at an unacceptable risk as a participant in the trial

          -  Current pharmacologic vitamin D2 or D3 intake &gt; 800 IU per day or use of calcitriol
             at any dose over the past four weeks prior to randomization

          -  Cyclophosphamide or IV glucocorticoid exposure within 12 weeks prior to randomization

          -  Any BILAG A or B manifestation with the exception of a BILAG B mucocutaneous
             manifestation at screening, and excluding the renal BILAG criteria (see criterion #5,
             below)

          -  Significant renal insufficiency defined as:

             i. Estimated GFR &lt; 60 mL/min/1.73m2 [95] or estimated GFR &lt; 90 mL/min/1.73m2 with a
             reduction of the GFR by &gt; 15% from the last measurement. ii. Urine dipstick value of
             2+ or higher for protein, unless this is a stable value from the last measurement or,
             urine protein-creatinine ratio ≥ 50 mg/mmol unless the value
             represents an improvement of ≥ 25% from the last measurement.

          -  Rituximab or belimumab exposure use within 24 weeks prior to randomization

          -  The following laboratory parameters at the Screening visit:

               -  Platelets &lt; 50,000; WBC &lt; 2,500; ANC &lt; 1,000

               -  Hemoglobin &lt; 9 mg/dL

               -  ALT, AST, bilirubin &gt; 2x ULN

               -  Hypercalcemia (Calcium &gt; ULN)

               -  Hypercalciuria (urinary calcium/creatinine ratio &gt; 0.2)

          -  Primary hyperparathyroidism (known)

          -  History of nephrolithiasis (known)

          -  Diabetes mellitus requiring insulin therapy

          -  Medications that interfere with vitamin D absorption (refer to Section 5.7,
             Prohibited Medications, for details)

          -  History of vertebral compression fractures (known)

          -  Pregnancy (girls ≥ 11 years of age must have a negative urine/serum pregnancy test)

          -  A history of non-adherence/non-compliance

          -  Other investigational drug and/or treatment during the four weeks or seven half-lives
             of the other investigational drug prior to the start of study product dosing (Day 0),
             whichever is the greater length of time to enrollment

          -  Current diagnosis of cancer or chronic infection such as Hepatitis B, Hepatitis C, or
             tuberculosis

          -  Treatment with digoxin

          -  Flu vaccination within one week prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon M Burnham, MD, MSCE</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emily Von Scheven, MD, MAS</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Cabrera</last_name>
      <phone>323-361-5958</phone>
      <email>ancabrera@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Bracha Shaham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Merkel</last_name>
      <phone>650-736-0644</phone>
      <email>merkel@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Christy Sandborg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Carlton</last_name>
      <phone>415-502-7685</phone>
      <email>CarltonD@peds.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Emily von Scheven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Thomas</last_name>
      <phone>773-880-4360</phone>
      <email>ethomas@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Marisa Klein-Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Puplava</last_name>
      <phone>773-702-2879</phone>
      <email>rpuplava@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Onel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Hudgins</last_name>
      <phone>317-274-2172</phone>
      <email>abamford@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Chira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arisa Kapedani</last_name>
      <phone>718-741-2456</phone>
      <email>akapedan@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jay Mehta, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afshin Zartoshti</last_name>
      <email>az2200@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Imundo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbra Murante, MS, RN</last_name>
      <phone>585-273-3462</phone>
      <email>barbra_murante@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>David Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Wootton, RN-BC RSCN</last_name>
      <phone>919-684-2575</phone>
      <email>janet.wootton@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Shanberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Tress</last_name>
      <phone>267-426-8153</phone>
      <email>tressj@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>John Burnham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evin Shirley</last_name>
      <phone>214-456-9501</phone>
      <email>evin.shirley@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Tracey Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Henstorf, BA, CCRC</last_name>
      <phone>206-987-2057</phone>
    </contact>
    <investigator>
      <last_name>Anne Stevens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
